Urmond (NL), March 28, 2012

Royal DSM, the global Life Sciences and Materials Sciences company, and NOM Finance have made a follow-on investment in IQ Therapeutics BV, a Netherlands-based biotech company that develops new innovative antibodies, effective in combating life-threatening infectious diseases. Financial details of the investment will not be disclosed.

IQ Therapeutics has completed the dosing of antibody IQNLF in a Phase I clinical trial. A total of 36 healthy volunteers participated in the randomized, placebo controlled, double blind, single dose-escalating study, intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IQNLF. The dosing has been completed successfully and doses up to 7.5 mg/kg have been administered, as per protocol.

With the dosing of the first volunteers, Dutch pharmaceutical IQ Therapeutics announced today the initiation of a Phase I clinical trial for IQ-DAA (a combination of two monoclonal human antibodies), a medicine directed against anthrax.